Current advances in colorectal cancer treatment: a review of recent clinical trials
Marcin Piotrowski1, Kinga Suska1, Damian Jacenik2
1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Introduction:
This review evaluates recent therapeutic advances in colorectal cancer (CRC), with a focus on late-phase clinical trials published between January 2024 and March 2025. The objective was to synthesize emerging data on chemotherapy, immunotherapy, targeted therapy, in metastatic colorectal cancer (mCRC) and locally advanced rectal cancer (LARC).
Areas Covered:
Notable findings include durable survival with pembrolizumab and nivolumab + ipilimumab in MSI-H/dMMR mCRC, efficacy of fruquintinib in refractory disease, and promising early outcomes with SCRT-based immunochemotherapy in LARC.
Expert Opinion:
Recent trials support precision oncology in CRC, highlighting durable benefits of targeted and immune therapies. However, heterogeneity in trial designs and underrepresentation of real-world populations limit generalizability.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Drugs for Treatment of Ulcerative Colitis in IBD
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...


